Infliximab counteracts tumor necrosis factor-α-enhanced induction of matrix metalloproteinases that degrade claudin and occludin in non-pigmented ciliary epithelium

Biochemical Pharmacology

Volumn 85, Issue 12, 2013, Pages 1770-1782

  Yamada, Hiroshi ^a   Yoneda, Masahiko ^b   Inaguma, Shingo ^a   Watanabe, Daisuke ^a   Banno, Shogo ^a   Yoshikawa, Kazuhiro ^a   Mizutani, Keigo ^a   Iwaki, Masayoshi ^a   Zako, Masahiro ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b AICHI PREFECTURAL UNIVERSITY   (Japan)

Author keywords

Blood aqueous barrier (BAB); Infliximab; Matrix metalloproteinase (MMP); Non pigmented ciliary epithelial cells; Tumor necrosis factor alpha (TNF )

Indexed keywords

CLAUDIN 1; GELATINASE B; INFLIXIMAB; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; OCCLUDIN; PROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD EYE BARRIER; CILIARY BODY EPITHELIUM; CILIATED EPITHELIUM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GELATIN ZYMOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TIGHT JUNCTION; UVEA; ZYMOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CILIARY BODY; CLAUDIN-1; DOWN-REGULATION; ENZYME INDUCTION; EPITHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; OCCLUDIN; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878868605     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.04.006     Document Type: Article

References (48)

1. J.L. Mege, N. Dilsen, V. Sanguedolce, A. Gul, P. Bongrand, and H. Roux Overproduction of monocyte-derived TNF-α, IL-6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects J Rheumatol 20 1993 1544 1549 (Pubitemid 24027329)
2. B. Turan, H. Gallati, H. Erdi, A. Gurler, B.A. Michel, and P.M. Villiger Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological marker of disease activity J Rheumatol 24 1997 128 132 (Pubitemid 27059870)
3. C. Evereklioglu, H. Er, Y. Türköz, and M. Cekmen Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease Mediators Inflamm 11 2002 87 93 (Pubitemid 34526411)
4. M.O. Oztas, M. Onder, M.A. Gurer, N. Bukan, and B. Sancak Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease Clin Exp Dermatol 30 2005 61 63 (Pubitemid 40188321)
5. Y. Ozdamar, N. Berker, G. Bahar, E. Soykan, T. Bicer, and S.S. Ozkan Inflammatory mediators and posterior segment involvement in ocular Behcet disease Eur J Ophthalmol 19 2009 998 1003
6. B.T. Gabelt, and P.L. Kaufman Production and flow of aqueous humor L.A. Levin, S.F. Nilsson, J.N. Ver Hoeve, S.M. Wu, Adler's physiology of the eye 11th ed 2011 Saunders Elsevier New York 274 307
7. C.E. Riva, A. Alm, and C.J. Pournaras Ocular circulation L.A. Levin, S.F. Nilsson, J.N. Ver Hoeve, S.M. Wu, Adler's physiology of the eye 11th ed. 2011 Saunders Elsevier New York 243 273
8. H. Li, M. Yoneda, M. Takeyama, I. Sugita, H. Tsunekawa, and H. Yamada Effect of infliximab on tumor necrosis factor-alpha-induced alterations in retinal microvascular endothelial cells and retinal pigmented epithelial cells J Ocul Pharmacol Ther 26 2010 549 556
9. P.P. Sfikakis, P.G. Theodossiadis, C.G. Katsiari, P. Kaklamanis, and N.N. Markomichelakis Effect of infliximab on sight-threatening panuveitis in Behçet's disease Lancet 358 2001 295 296 (Pubitemid 32738970)
10. S. Ohno, S. Nakamura, S. Hori, M. Shimakawa, H. Kawashima, and M. Mochizuki Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis J Rheumatol 31 2004 1362 1368 (Pubitemid 38879203)
11. I. Tugal-Tutkun, A. Mudun, M. Urgancioglu, S. Kamali, E. Kasapoglu, and M. Inanc Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial Arthritis Rheum 52 2005 2478 2484 (Pubitemid 41117435)
12. E.W. Lindstedt, G.S. Baarsma, R.W. Kuijpers, and P.M. van Hagen Anti-TNF-alpha therapy for sight threatening uveitis Br J Ophthalmol 89 2005 533 536 (Pubitemid 40569703)
13. H. Al-Rayes, R. Al-Swailem, M. Al-Balawi, N. Al-Dohayan, S. Al-Zaidi, and M. Tariq Safety and efficacy of infliximab therapy in active Behcet's uveitis: an open-label trial Rheumatol Int 29 2008 53 57
14. K.F. Tabbara, and A.I. Al-Hemidan Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease Am J Ophthalmol 146 2008 845 850
15. T. Handa, H. Tsunekawa, and M. Zako Cataract surgery in Behçet's disease patients one week after infliximab administration Case Rep Ophthalmol 2 2011 176 178
16. T. Handa, H. Tsunekawa, M. Yoneda, D. Watanabe, T. Mukai, and M. Yamamura Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab Clin Exp Rheumatol 29 2011 S58 S63
17. A. Koike, T. Handa, and M. Zako Trabeculotomy in a Behçet's disease patient one week after infliximab administration Case Rep Ophthalmol 3 2012 151 155
18. C. Bucolo, S. Cuzzocrea, E. Mazzon, and A.P. Caputi Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats Invest Ophthalmol Vis Sci 44 2003 1178 1184 (Pubitemid 36297838)
19. E.B. Suhler, J.R. Smith, T.R. Giles, A.K. Lauer, M.S. Wertheim, and D.E. Kurz Infliximab therapy for refractory uveitis: 2-year results of a prospective trial Arch Ophthalmol 127 2009 819 822
20. S. Tsukita, Y. Yamazaki, T. Katsuno, A. Tamura, and S. Tsukita Tight junction-based epithelial microenvironment and cell proliferation Oncogene 27 2008 6930 6938
21. M.J. Karim, S. Biswas, P. Bhattacherjee, and C.A. Paterson Comparison of tight junction protein expression in the ciliary epithelia of mouse, rabbit, cat and human eyes Biotech Histochem 86 2011 161 167
22. A. Hashizume, T. Ueno, M. Furuse, S. Tsukita, Y. Nakanishi, and Y. Hieda Expression patterns of claudin family of tight junction membrane proteins in developing mouse submandibular gland Dev Dyn 231 2004 425 431 (Pubitemid 39238069)
23. J.A. Shields, R.C. Eagle Jr., C.L. Shields, and P. De Potter Acquired neoplasms of the nonpigmented ciliary epithelium (adenoma and adenocarcinoma) Ophthalmology 103 1996 2007 2016 (Pubitemid 27024621)
24. S. Mansoor, and A. Qureshi Ciliary body adenoma of non-pigmented epithelium J Clin Pathol 57 2004 997 998 (Pubitemid 39208258)
25. C.E. Riva, A. Ail, and C.J. Pournaras Ocular circulation L.A. Levin, F.E. Nilsson Siv, J. Ver Hoeve, S.M. Wu, Adler's physiology of the eye 2011 Saunders Elsevier Edinburgh 243 273
26. H. Ando, S.S. Twining, B.Y. Yue, X. Zhou, M.E. Fini, and T. Kaiya MMPs and proteinase inhibitors in the human aqueous humor Invest Ophthalmol Vis Sci 34 1993 3541 3548 (Pubitemid 24011990)
27. M. Määttä, T. Tervahartiala, E. Vesti, J. Airaksinen, and T. Sorsa Levels and activation of matrix metalloproteinases in aqueous humor are elevated in uveitis-related secondary glaucoma J Glaucoma 15 2006 229 237
28. N. Di Girolamo, M.J. Verma, P.J. McCluskey, A. Lloyd, and D. Wakefield Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis Curr Eye Res 15 1996 1060 1068 (Pubitemid 26360044)
29. Y.G. El-Shabrawi, W.G. Christen, and S.C. Foster Correlation of metalloproteinase-2 and -9 with proinflammatory cytokines interleukin-1b, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis Curr Eye Res 20 2000 211 214 (Pubitemid 30209653)
30. M. Takeyama, M. Yoneda, M. Takeuchi, Z. Isogai, A. Ohno-Jinno, and T. Kataoka Increase in matrix metalloproteinase-2 level in the chicken retina after laser photocoagulation Lasers Surg Med 42 2010 433 441
31. I.H. Pang, P.E. Hellberg, D.L. Fleenor, N. Jacobson, and A.F. Clark Expression of matrix metalloproteinases and their inhibitors in human trabecular meshwork cells Invest Ophthalmol Vis Sci 44 2003 3485 3493 (Pubitemid 36909786)
32. K.E. Keller, M. Aga, J.M. Bradley, M.J. Kelley, and T.S. Acott Extracellular matrix turnover and outflow resistance Exp Eye Res 88 2009 676 682
33. E. Daniel, M. Pistilli, S.S. Pujari, R.O. Kaçmaz, R.B. Nussenblatt, and J.T. Rosenbaum Risk of hypotony in noninfectious uveitis Ophthalmology 119 2012 2377 2385
34. A. Arida, K. Fragiadaki, E. Giavri, and P.P. Sfikakis Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients Semin Arthritis Rheum 41 2011 61 70
35. E. Apostolidou, E. Paraskeva, K. Gourgoulianis, P.A. Molyvdas, and C. Hatzoglou Matrix metalloproteinases 2 and 9 increase permeability of sheep pleura in vitro BMC Physiol 12 2012 2
36. E. Mazzon, G.C. Sturniolo, D. Puzzolo, N. Frisina, and W. Fries Effect of stress on the paracellular barrier in the rat ileum Gut 51 2002 507 513
37. V. Asgrimsson, T. Gudjonsson, G.H. Gudmundsson, and O. Baldursson Novel effects of azithromycin on tight junction proteins in human airway epithelia Antimicrob Agents Chemother 50 2006 1805 1812
38. J. Li, L. Ye, X. Wang, J. Liu, Y. Wang, and Y. Zhou Epigallocatechin gallate inhibits endotoxin-induced expression of inflammatory cytokines in human cerebral microvascular endothelial cells J Neuroinflammation 9 2012 161
39. J. Liu, X. Jin, K.J. Liu, and W. Liu Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage J Neurosci 32 2012 3044 3057
40. J. Kim, C.S. Kim, Y.M. Lee, K. Jo, S.D. Shin, and J.S. Kim Methylglyoxal induces hyperpermeability of the blood-retinal barrier via the loss of tight junction proteins and the activation of matrix metalloproteinases Graefes Arch Clin Exp Ophthalmol 250 2012 691 697
41. S. Feng, J. Cen, Y. Huang, H. Shen, L. Yao, and Y. Wang Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins PLoS ONE 6 2011 e20599
42. T. Martins, S. Baptista, J. Gonçalves, E. Leal, N. Milhazes, and F. Borges Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9 Brain Res 1411 2011 28 40
43. Y. Yang, and G.A. Rosenberg MMP-mediated disruption of claudin-5 in the blood-brain barrier of rat brain after cerebral ischemia Methods Mol Biol 762 2011 333 345
44. X.K. Tu, W.Z. Yang, R.S. Liang, S.S. Shi, J.P. Chen, and C.M. Chen Effect of baicalin on matrix metalloproteinase-9 expression and blood-brain barrier permeability following focal cerebral ischemia in rats Neurochem Res 36 2011 2022 2028
45. J. Duran-Vilaregut, J. del Valle, G. Manich, A. Camins, M. Pallàs, and J. Vilaplana Role of matrix metalloproteinase-9 (MMP-9) in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease Neuropathol Appl Neurobiol 37 2011 525 537
46. T. Higashida, C.W. Kreipke, J.A. Rafols, C. Peng, S. Schafer, and P. Schafer The role of hypoxia-inducible factor-1α, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury J Neurosurg 114 2011 92 101
47. R. Xu, X. Feng, X. Xie, J. Zhang, D. Wu, and L. Xu HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9 Brain Res 1436 2012 13 19
48. Y. Gu, G. Zheng, M. Xu, Y. Li, X. Chen, and W. Zhu Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity and blood-brain barrier permeability in focal cerebral ischemia and reperfusion injury J Neurochem 120 2012 147 156